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Abstract
Localized prostate cancer (CaP) can be cured using several strategies. However, the need to identify active substances
in advanced tumor stages is tremendous, as the outcome in such cases is still disappointing. One approach is to
deliver human tumor antigen–targeted therapy, which is recognized by T cells or antibodies. We used data mining
of the Cancer Immunome Database (CID), which comprises potential immunologic targets identified by serological
screening of expression libraries. Candidate antigens were screened by DNAmicroarrays. Genes were then validated
at the protein level by tissue microarrays, representing various stages of CaP disease. Of 43 targets identified by CID,
10 showed an overexpression on the complementary DNA array in CaP metastases. The RHAMM (CD168) gene,
earlier identified by our group as an immunogenic antigen in acute and chronic leukemia, also showed highly signifi-
cant overexpression in CaPmetastases compared with localized disease and benign prostatic hyperplasia. At the pro-
tein level, RHAMM was highest in metastatic tissue samples and significantly higher in neoplastic localized disease
comparedwith benign tissue. High RHAMMexpressionwas associatedwith clinical parameters known to be linked to
better clinical outcome. Patients with high RHAMM expression in the primaries had a significantly lower risk of bio-
chemical failure. The number of viable cells in cell cultures was reduced in blocking experiments using hormone-
sensitive and hormone-insensitive metastatic CaP cell lines. Acknowledging the proven immunogenic effects of
RHAMM in leukemia, this antigen is intriguing as a therapeutic target in far-advanced CaP.
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Abbreviations: CaP, prostate cancer; cDNA, complementary DNA; CID, Cancer Immunome Database; DU145, hormone-independent CaP cell line; LNCaP, hormone-
sensitive CaP cell line; PC3, hormone-independent CaP cell line; PSA, prostate-specific antigen; RHAMM/CD168, receptor of hyaluronan-mediated motility (HMMR); SEREX,
serological identification of antigens by recombinant expression cloning; TMA, tissue microarray
Address all correspondence to: Rainer Kuefer, MD, FEBU, Professor of Urology, Department of Urology, University of Ulm, Prittwitzstr. 43, 89075 Ulm, Germany.
E-mail: rainer.kuefer@uni-ulm.de
1All authors of the article have declared that there are no commercial affiliations, stock interests, or patent licenses of potential conflict of interest with the presented work. There
are no financial interests of a company whose product has been used for studies in the work presented in the article.
2These authors have equally contributed to the study.
Received 28 April 2009; Revised 21 June 2009; Accepted 22 June 2009
Copyright © 2009 Neoplasia Press, Inc. All rights reserved 1522-8002/09/$25.00
DOI 10.1593/neo.09694
www.neoplasia.com
Volume 11 Number 9 September 2009 pp. 956–963 956
Introduction
In western countries, the prevalence of prostate cancer (CaP) is high
and has been seen to increase with age. One in six men will have their
conditions diagnosed with CaP during their lifetime, and thus, CaP is
the leading cause of male cancer-related death, second only to lung
cancer [1–3]. Prostate cancer is curable when the tumor is localized
to the prostate gland and when treated at an early stage. Unsuspected
extracapsular or metastatic disease may significantly increase the risk of
primary treatment failure. This risk is especially high if the patient has
one or more of the following risk factors: a serum prostate-specific
antigen (PSA) level greater than 20 ng/ml, a Gleason score higher than
7, locally advanced disease (clinical stage T3/T4), and extensive disease
on prostate biopsy [4].
New therapeutic approaches for localized CaPs and for locally ad-
vanced or metastatic diseases have been proposed for research. Nowa-
days, the primary concept in metastatic CaP is control of tumor growth
based on hormonal withdrawal. Luteinizing hormone-releasing hor-
mone agonists act the same way as orchidectomy; other drugs are
peripheral inhibitors of androgens. The role of androgen deprivation
by orchidectomy is eclipsed by the medicamentous suppression of an-
drogen production. If resistance occurs, tumor cells show an androgen-
independent progression. Current systemic therapies with proven
efficacy are limited to docetaxel-containing chemotherapy. In combina-
tionwith low-dose prednisone, docetaxel is recommended for patientswith
metastatic hormone-refractory CaP (HRPC). This regimen showed a
limited survival benefit and is often limited by toxicity in the elderly [5].
The median survival of patients with HRPC is still between 18 and
20 months [6]. Despite new promising results of platin-based chemo-
therapy (satraplatin) [7–11], it is crucial to intensify research in targeted
therapy. At present, advanced CaP is an incurable disease and treatment
objective focuses on palliation.
Consequently, the development of new treatmentmodalities especially
for metastatic or locally advanced CaP is important. The development of
low-toxicity therapeutic options in HRPC is an unmet medical need.
Novel targets and therapeutic approaches in advanced CaP have
changed during the last decade. Some naturally occurring substances,
such as retinoids or butyrates, show effects on CaP [12], which can
induce cell cycle arrest, differentiation, and apoptosis in many tumor
cell types, while having a favorable safety profile in humans [13]. New
therapeutic options such as nucleotid-based targeted therapies, small-
molecule inhibitors [14–17], antiangiogenic agents such as sunitinib
[18–21], and novel cytotoxic therapeutics such as satraplatin [8,9,11]
were developed that show promise in the management of patients with
advanced CaP and are in clinical trials or approved. Likewise, new-
generation expression profile tools give better insight into CaP signa-
tures and unclose potential new targets [22].
Another approach illuminates the immunologic site of cancer [23–
26]. In other malignancies, such as breast cancer and melanoma,
the immunologic approach has shown encouraging results. Immuno-
therapeutical approaches are of interest in advanced stages of CaP. They
are also used in adjuvant setting after curative therapy, when some
tumor load is still present, and hormonal manipulation is used to re-
duce the risk of recurrent disease.
Database analysis using Cancer Immunome Database (CID)1 yields
numerous tumor-associated antigens (TAAs) in different kinds of can-
cer. Similar to other targeted therapies, an immunomodulatory ap-
proach could deploy CaP-specific characteristics. Recent studies have
shown autoantibodies against peptides derived from CaP tissue that
could be used as basis for a screening test [27,28]. New immunologic
approaches could also deliver promising therapeutic targets in the
future. A potential target in CaP called the receptor of hyaluronan-
mediated motility (RHAMM, also known as CD168 or HMMR)
has been identified. This had been described earlier as an immunogenic
antigen in acute and chronic leukemia [29] and breast cancer [30] and
was shortly reported in a pathway with androgen receptor in CaP
[31,32]. The potential use of RHAMM as target for an immunologic
therapy is presented in phase 1 studies including hematological diseases
such as acute myeloid leukemia, myelodysplastic syndrome, and mul-
tiple myeloma. The study performed by Schmitt et al. [33] shows
RHAMM as a promising target by observed immunologic and clinical
response using RHAMM R3 vaccination.
Every new systemic approach should mandate that new targets are
selectively overexpressed in tumor cells to minimize the adverse effects
of knockdown, such as CML 28 [34] or RHAMM [31,32] for an
immunologic approach. A number of recently developed approaches
to antitumoral immunotherapy are being investigated as potential treat-
ments for advanced CaP [35].
On the basis of published experience of our coworkers, we set out in
this study to investigate the potential immunogenic role of RHAMM
in patients with CaP disease in the clinical setting.
Materials and Methods
Sample Collection
Clinical samples were provided from the radical prostatectomy series
and Rapid Autopsy Program at the University of Michigan. The speci-
mens were processed within 20 minutes after surgical resection. Al-
ternate sections of the prostate gland were submitted for histologic
review. The remaining sections were snap-frozen and stored. All sam-
ples used for complementary DNA (cDNA) expression array analysis
and Western Blot analysis were evaluated by the study pathologists.
Clinical and pathology data for all patients were acquired with approval
from the institutional review board at the University of Michigan and
maintained on a secure relational database [36]. The Rapid Autopsy
Program, which allowed men with advanced CaP to consent to an
autopsy immediately after death, was developed. This procedure has
previously been described in detail [37].
Primary CaP samples, as well as lymph node metastases, were con-
tributed from the University of Ulm, Germany, for the construction
of tissue microarrays (TMAs) [38].
Identification of Potential Immunologic Targets
Data mining in CID-related databases was performed to identify
potential immunologic target structures. Consequently, candidate anti-
gens were screened by their own cDNA microarrays [39–41] and cross-
checked using expression profile databases of several research groups that
are available for the research community (www.oncomine.org) [42,43].
cDNA Array Expression Profile
RNA was isolated from 71 prostate tissue samples representing
benign prostatic hyperplasia, localized CaP, and metastatic CaP. The
construction of the cDNA microarrays has been previously explained
[39,44]. In brief, plasmid templates for a maximum of 20K transcripts
were isolated from bacterial clones and inserts amplified by polymerase
1In 2002, the Academy of Cancer Immunology and the Ludwig Institute for Cancer Re-
search became the cosponsors of a new database, the Cancer Immunome Database (CID),
which replaced the SEREX database (http://ludwig-sun5.unil.ch/CancerImmunomeDB/).
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chain reaction. Purified polymerase chain reaction fragments were
printed onto glass slides and cross-linked with the DNA targets. cDNA
generated from localized CaP samples and metastatic tissue samples
were labeled with a distinguishable fluorescent dye and hybridized to
the cDNA microarray. The cDNA microarray was analyzed using a
scanner, and fluorescence ratios were determined for each gene. Color
intensities were converted into ratios of gene expression. These ratios
were imported into a database for further analysis.
Tissue Microarray
Formalin-fixed, paraffin-embedded tissue blocks with tumor samples
from CaP and lymph node metastases were selected. Each case was iden-
tified using patient reports as part of this institutional review board–
approved project (University of Ulm and University of Michigan).
One pathologist (M.A.R.) reviewed the hematoxylin and eosin–stained
slides and was responsible for circling areas of CaP, metastases or benign
prostate, which were then used as template for the TMA.
To take tumor heterogeneity into account, a minimumof three TMA
cores (0.6 mm in diameter) were sampled from each donor block using
a validated sampling method [45].
TMAs were constructed using a manual tissue arrayer (Beecher
Instruments, Silver Spring, MD) as previously described [46] with a
total of approximately 900 tissue cores from 15 benign prostate sam-
ples, 220 primary CaP, and 47 lymph node metastases. For tissue
processing, standard biotin-avidin complex immunohistochemistry
was performed using a RHAMMantibody (E-19; sc-16170; Santa Cruz
Biotechnology, Santa Cruz, CA). Staining intensity was determined
by the semiautomated quantitative image analysis system (ACIS II;
Clarient Chromavision Medical Systems, San Juan Capistrano, CA)
[47]. The output data of RHAMMexpression are represented by a con-
tinuous scale of 3,3′-diaminobenzidine (DAB) brown area and average
DAB staining intensity for each core, ranging from 0 to 255. The
RHAMMexpression intensity of each array was normalized by calculat-
ing the z-score for each core. The z-score normalization functions to
equalize the immunohistochemical experiments on different TMAs be-
cause of the variability of staining. The converted z-scores were then
aggregated into one large data set. Tissue cores of some patients were
represented on more than one TMA, and after combining all z-values
for each patient, the mean z-score intensity of DAB staining for each
patient was determined.
Cell Lines and Cell Cultures
In cell culture experiments, hormone-sensitive (LNCaP) and hormone-
independent metastatic (PC3 and DU145) cancer cell lines were used.
The cell lines were cultured in RPMI 1640 (PromoCell, Heidelberg,
Germany) including 5% FBS.
Growth Inhibition and Cell Viability Assay
LNCaP (5 × 103), PC3 (2 × 103), and DU145 (4 × 103) cells were
grown in microtiter plates and treated with increasing concentrations
(0, 5, and 10 μg/ml) of RHAMM-specific antibody E-19 (sc-16170;
Santa Cruz Biotechnology) on day 1 for 72 hours. According to the
manufacturer’s information, on day 4, growth inhibition was correlated
to absorbance determined using the XTT assay Cell Proliferation Kit
(Roche Applied Science, Mannheim, Germany). The control was set
to 100%. The percentage of viable cells as mean values and SE is given
for repeated experiments.
Statistical Analysis
The RHAMM protein expression was evaluated using the mean
score result for each prostate tissue type per patient. To test for signifi-
cant differences, analysis of variance (ANOVA) was performed. To de-
termine association with clinical parameters, Mann-Whitney U tests
were performed. Statistical analyses were performed using SPSS (SPSS,
Inc, Chicago, IL). P values ≤ .01 were considered statistically significant.
Kaplan-Meier analysis was performed for RHAMM protein expres-
sion in the primary localized CaP and its association with biochemical
recurrence-free survival.
Results
CID and cDNA Analysis
CID data mining and own expression cloning experiments iden-
tified 43 genes with potential humoral response to CaP. Of 43 the
CID identified targets, 10 showed an overexpression on the Michigan
cDNA 20K chip in CaP metastases in compared with localized dis-
ease and benign prostatic hyperplasia (Table 1). One of these targets
was RHAMM.
On the basis of previous group experience and the reported value of
RHAMM in acute and chronic leukemia [29], as well as in breast
cancer [30], we focused our study on RHAMM. Own cDNA analy-
sis showed highly significant overexpression of RHAMM in CaP me-
tastases compared with localized disease and benign prostate tissue
(Figure 1). Data mining in Oncomine (www.oncomine.org) yielded a
similar expression profile with an overexpression of RHAMM in other
platforms. Yu et al. [48] found an overexpression of RHAMM in meta-
static CaP compared with normal prostate tissue or prostate carci-
nomas (P < .001). An overexpression of RHAMM on messenger RNA
level in CaP compared with normal prostate tissue was also shown by
La Tulippe et al. (P < .001) [49].
TMA for RHAMM (CD168)
For verification of RHAMM overexpression at the protein level,
TMAs were constructed with approximately 900 individual tissue cores
of localized CaP, CaP metastases, and benign prostatic hyperplasia.
Immunohistochemistry using anti-RHAMM antibody (E-19) showed
highest levels in metastatic tissue samples and significantly higher ex-
pression in neoplastic localized disease compared with benign tissue
Table 1. Overexpression on the 20K cDNA Array of Targets and Corresponding P Values in CaP
Metastases Compared with Localized Disease and Benign Prostatic Hyperplasia.
Target ANOVA Post hoc (Scheffé)
Benign Prostate Tissue vs
CaP Metastases
Localized CaP vs
CaP Metastases
BAP1 .094 NS NS
BRCA1 .156 NS NS
PSG2 .002 <.01 <.05
MPV17 .002 <.01 <.05
Stau2 .001 .01 <.01
Mark3 .025 NS <.05
MCM3 .019 NS <.05
PMSCL2 .010 NS .01
MAPK3 .109 NS NS
RHAMM .004 <.05 .01
For statistical analysis, a multifactorial ANOVA was performed.
Group factors: expression in benign prostate tissue samples, localized CaP, and CaP metastases.
Significance was approved with post hoc tests (Scheffé). On cDNA level, no significant differences
between localized CaP and benign prostate tissue were found.
NS indicates not significant.
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(P = .003). Staining intensity was determined with ACIS II as a marker
for protein expression of RHAMM. Staining resulted in a deep brown
color for high RHAMM protein levels as shown in Figure 2.
Association of RHAMM Expression and Clinical Parameters
Within the significantly RHAMM-overexpressing primary tumor
samples on the TMA, patients with higher RHAMM protein expres-
sion levels in primaries showed significantly lower risk of biochemical
failure (Figure 3). In addition, a higher expression of RHAMM was
associated with negative lymph node status, lower Tstadium, and lower
serum PSA at the time of diagnosis (Figure 4). These clinical parameters
are also known to be associated with better outcome.
Growth Inhibition and Cell Viability
In cell culture experiments, the number of viable cells determined
by XTT assay was reduced in blocking experiments using hormone-
sensitive (LNCaP) and hormone-independent metastatic (PC3 and
DU145) cancer cell lines. This was done by applying increasing con-
centrations of RHAMM-specific antibody (E-19). Higher antibody
concentrations resulted in a reduced number of viable cells in all cell
lines (Figure 5). The highest growth inhibition was found in LNCaP
cells with 82.7% viable cells at a concentration of 5 μg/ml and 58.1%
at 10 μg/ml of RHAMM-specific antibody.
Discussion
Initially, in this study, we used a reverse immunology approach to
identify immunogenic structures on CaP. This was possible courtesy
of the Ludwig Institute for Cancer Research, which provided open
World Wide Web access to SEREX (serological identification of anti-
gens by recombinant expression cloning)–defined TAAs. The proposal
that humoral responses can occur only with T-cell help has been proven
already in the first description of the SEREXmethod. This method also
picked the T-cell–activating antigens tyrosinase and MAGE-1 by this
serological screening approach [50]. Expression of the genes was re-
checked with potential humoral responses for messenger RNA expres-
sion based on a 20K cDNA chip provided by our collaborators at the
University of Michigan. The outcome resulted in 10 intersecting genes,
which fulfilled both criteria. However, of these immunoreactive mole-
cules, only a very few are suited as targets for immunotherapy.
There are several proteins within this list (Table 1), which play an
important role in the physiological cell metabolism or contribute to the
correct cell division such as MPV17 or MARK3, respectively [51,52].
This indicates that the presence of autoantibodies may result from un-
intended cell damage and suggests that this is rather a bystander effect
rather than a true augmentable immune response against malignant
cells. Thus, this observation gives rise to the question if this reverse
immunology approach, which has been used, is valid for the identifica-
tion of viable target antigens.
Conversely, autoantibody signatures might be useful in enhancing
the specificity and sensitivity of serological screening tests. This was
described by researchers from the University of Michigan, who found
Figure 2. (A) Mean protein expression of RHAMM in benign tissue,
localized CaP, and metastatic tissue is shown. Significant higher
protein levels of RHAMM were detected in localized CaP (P =
.003) and metastases (P < .001) compared with benign prostatic
hyperplasia. RHAMM was expressed higher in CaP metastases
compared with protein levels in localized CaP, although this did not
reach statistical significance. (B) Representative cores of low (left)
and high RHAMM expression (right) in on the TMA.
Figure 1. cDNA microarray expression analysis of RHAMM in be-
nign prostatic tissue (Benign), localized (Loc PCA), and metastatic
CaP specimen (PCA Mets). Significant overexpression of RHAMM
in metastases compared with localized prostatic cancer (P = .007)
or benign prostate tissue (P < .001).
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autoantibodies against α-methylacyl-CoA racemase in CaP patients and
showed that the specificity and sensitivity ofα-methylacyl-CoA racemase
was superior to that of PSA, especially in those patients with intermedi-
ate PSA levels [53]. In a more recent attempt to use CaP-specific auto-
antibodies as biomarkers in CaP patients, the same group developed a
22-phage peptide detector, which significantly added to the diagnostic
power of PSA alone, and this might be important in patients exhibiting
low PSA levels [27]. As a clinical impact, the number of unnecessary
biopsies might be reduced.
RHAMM has been added to the list as a potentially immunogenic
antigen in CaP for three reasons. First, it has been described as a TAA
in the year 2002, picked also by a SEREX-derived method, and it
displayed humoral responses in a wide range of tumors [29]. Second,
it showed a favorable expression profile with the placenta, thymus, and
testis, being the only normal tissues expressing this antigen. Finally,
after the identification of immunogenic peptides, RHAMM R3 has
made its way into a clinical phase 1 to 2 study in patients with hemato-
logical malignancies and led to immunologic effects in most patients
and to some clinical benefit [33,54].
There are several aspects of RHAMM, which are of particular inter-
est. RHAMM is a glycosaminoglycan and extracellular matrix molecule
that plays an essential role in cell growth, differentiation, and motility.
Overexpression of RHAMMis essential for ras-mediated transformation,
Figure 3. Kaplan-Meier analysis showed significant lower risk of bio-
chemical failure (log rank, P= .023; relative risk = 0.621) in patients
with high RHAMM expression in primary localized CaP (red = high
expression/black = low expression).
Figure 4. Protein expression of RHAMM on the TMAs was analyzed for the association with clinical parameters such as tumor stage
(T stage; A), lymph node status (N stage; B), and PSA (C) categorized using the mean PSA level as cutoff value. P values were calculated
based on the Mann-Whitney U test. (A) There is a strong association between RHAMM protein expression and tumor stage defined as
T2 and T3. Pathologic T3 tumors known to have worse outcome have a significant lower RHAMM expression (P= .01). (B) Lymph node–
positive patients have a significant lower protein expression in the primaries compared with patients without lymph node metastases at
the time of radical prostatectomy (P < .0001). (C) Patients with high PSA levels, known as an independent predictor for worse outcome,
have a significantly lower protein expression of RHAMM (P < .001).
Figure 5. Decreasing numbers of viable cells determined by the XTT
assay by exposure to increasing concentrations (5 and 10 μg/ml) of
a RHAMM-specific antibody (E-19) in LNCaP, PC3, and DU145 cell
lines. Reduced viable cells occurred with increasing antibody con-
centration. Relative cell amounts are shown. The control was set to
100% of viable cells.
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and it is associated with the development of metastases [55]. More-
over, signaling through RHAMM and its downstream signal molecules,
including ROK1, Gab-1, PI3K*p110a, and eIF4E3, particularly en-
hanced the progression of androgen-independent CaP cell lines in sev-
eral aspects [32].
Therefore, immune therapies targeting RHAMM might target not
only an immunogenic antigen but also a gene critically involved in cell
cycle, differentiation, and proliferation [56].
The key point in the present study is the analysis of RHAMM ex-
pression on cDNA and protein levels in a large amount of samples.
In our cDNA expression profiles, we found a highly significant over-
expression of RHAMM in CaP metastases compared with localized
CaP or benign prostate tissue. This finding was consistent with data
revealed by data mining from several other microarray platforms acces-
sible through the Oncomine database (www.oncomine.org) [42,43].
To confirm the Genomics data with Proteomics, we subjected an even
larger cohort of 282 tissue samples from CaP patients to TMAs and
again found a significant overexpression of RHAMM primary tumor
samples and even higher in lymph node metastases, although it did
not reach statistical significance. These data suggest that RHAMM
is upregulated in the malignant phenotype and in disease progression,
and it might additionally be involved in the development of metas-
tases. These results are consistent to TMA data from Lin et al. [31,32],
who also found an overexpression of RHAMM in samples of CaP com-
pared with benign prostatic tissue. The same group impressively demon-
strated the role of RHAMMdownstream through the ROK-PI3K-eIF4E
signaling cascade in clinical staging, cell proliferation, cell invasion, and
metastasis of advanced CaP [32].
Overexpression of RHAMM seems not to be specific for CaP only
because different studies have shown that RHAMMmight be an inter-
esting target in different kinds of solid tumors such as head and neck
squamous cell carcinomas [57], breast cancer [30], or even colorectal
cancer [58].
When comparing RHAMM protein expression with clinical data, we
observed contradictory results at a first glance because further analysis in
primary tumors revealed that higher expression levels are associated with
a longer time window of biochemical recurrence-free survival. How-
ever, this observation could be explained by the concepts of immuno-
surveillance and immunoediting. The oncogenesis of an individual
tumor is the result of a continuous interaction between potentially di-
viding malignant cells and host lymphocytes, which could display several
states of responsiveness. In an immunoediting process, three phases of
interaction have been proposed: tumor cell elimination, equilibrium,
and tumor cell escape [59]. After removal of the primary tumor, po-
tentially widespread single cells that express a significant amount of
RHAMM peptides in the context of a surface major histocompatibility
complexmolecule and sufficient costimulatorymoleculesmight be elimi-
nated by the host defense, that is, by RHAMM-specific cytotoxic T lym-
phocytes. This could have led to sustained tumor cell elimination and
subsequently to the prolonged biochemical failure-free survival.
Similarly, in patients experiencing acute myeloid leukemia, the
overexpression of at least 1 TAA (RHAMM, CA9/G250, or PRAME)
improved even overall survival, and this might also reflect sustained im-
munologic control of minimal residual disease [60].
The fact that CaPs with higher T and N stages displayed a signifi-
cantly lower amount of RHAMM protein in primaries on the TMAs
might be also explained with the long-lasting interaction of RHAMM
and host cytotoxic T lymphocyte, finally leading to tumor escape
with an outgrowth of RHAMM-negative tumor cells. The well-known
heterogeneity within CaPs with, that is, different Gleason patterns,
may facilitate such events of immunoselection. Because we did not pro-
vide proof of a strong T-cell pressure against RHAMM in CaP patients
by themeans of enzyme-linked ImmunoSpot assay or tetramer staining,
in the present study, the proposed mechanism of T-cell–based immuno-
selection remains a model so far.
However, if RHAMM expression truly leads to a prolonged time
to progression after the resection of the primary due to immunologic
control, an augmentation of the T-cell response against these antigens
by a vaccination protocol might be of further benefit for the patients.
It is most likely that the patients’ greatest benefit would be seen in the
adjuvant setting with a low tumor burden being present, that is, small
metastases in lymph nodes or a positive margin. Another potential
therapeutic consequence of RHAMM overexpression is founded on
the observation that incubation of CaP cell lines with a RHAMM-
specific antibody reduced the viability of both hormone-sensitive and
hormone-insensitive CaP cells cell lines. Consistently, it was demon-
strated by Lin et al. [31,32] that downstream blockade of the RHAMM
pathway by the ROCK inhibitor Y-27632 or anti-ROCK1 micro RNA
was able to abolish cancer cell proliferation, invasion, and metastasis in
the same cell lines used in our study.
Recently, the same group showed that androgen stimulation leads in
overexpression of RHAMMand hyaluronan-stimulated activation of the
RHAMM-ROCK1 cascade in LNCaP cells, suggesting that RHAMM
plays a role in androgen-dependent as well as in castration-resistant stage
of CaP [31].
Summarizing, the overexpression of RHAMM at the protein level
was found in both localized CaP and metastatic sites. Whereas higher
protein levels in primaries are associated with better clinical outcome,
highest levels were found in lymph node metastases, an advanced stage
of disease. This illustrates that RHAMMmight also be a target suitable
for monoclonal antibody therapy in advanced CaP.
Conclusions
We identified 10 differentially overexpressed potential immunogenic
targets in CaP by data mining and own cDNA array analysis. RHAMM
(CD168) was overexpressed at the cDNA level as well as at the protein
level in the metastatic aspect compared with localized CaP or benign
tissue. The protein overexpression of RHAMM was associated with a
lower risk of biochemical failure. Expression of RHAMM also had an
association with clinical parameters known to be associated with better
clinical outcome such as favorable T stage, no lymph node metastases,
and lower PSA serum level.
In cell culture, numbers of viable cells were reduced in blocking
experiments with the RHAMM-selective antibody (E-19) using
hormone-sensitive (LNCaP) and hormone-insensitive metastatic (PC3
and DU145) CaP cell lines.
The pathways involved in the intracellular signaling cascade medi-
ated by RHAMM in CaP are currently under analysis. Acknowledg-
ing the proven immunogenic effects of RHAMM in clinical trials for
hematological diseases, this antigen might be a promising therapeutic
target in the adjuvant setting or even in advanced CaP.
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